Maximum Low-density Lipoprotein Cholesterol Lowering Capacity Achievable with Drug Combinations. When 50 Plus 20 Equals 60;Máxima reducción de colesterol unido a lipoproteínas de baja densidad alcanzable con combinaciones farmacológicas. Cuando 50 más 20 suma 60

Revista Espanola de Cardiologia

Volumn 69, Issue 3, 2016, Pages 342-343

  Masana, Lluis ^a   Ibarretxe, Daiana ^a   Plana, Nuria ^a  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

DRUG COMBINATION; LETTER; BLOOD; COMBINATION DRUG THERAPY; HUMAN; HYPERCHOLESTEROLEMIA; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; EZETIMIBE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; TREATMENT OUTCOME;

EID: 84961971177     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/j.recesp.2015.11.016     Document Type: Article

References (6)

1. C.P. Cannon, M.A. Blazing, R.P. Giugliano, A. McCagg, J.A. White, P. Theroux, et al. IMPROVE-IT Investigators Ezetimibe added to statin therapy after acute coronary syndromes N Engl J Med. 372 2015 2387 2397
2. B.A. Ference, F. Majeed, R. Penumetcha, J.M. Flack, and R.D. Brook Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial mendelian randomization study J Am Coll Cardiol. 65 2015 1552 1561
3. L. Masana, J. Pedro-Botet, F. Civeira IMPROVE-IT clinical implications Should the "high-intensity cholesterol-lowering therapy" strategy replace the "high-intensity statin therapy"? Atherosclerosis. 240 2015 161 162
4. J.G. Robinson, M. Farnier, M. Krempf, J. Bergeron, G. Luc, M. Averna, et al. ODYSSEY LONG TERM Investigators Efficacy and safety of alirocumab in reducing lipids and cardiovascular events N Engl J Med. 372 2015 1489 1499
5. M.S. Sabatine, R.P. Giugliano, S.D. Wiviott, F.J. Raal, D.J. Blom, J. Robinson, and et al. Open-label Study of Long-term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events N Engl J Med. 372 2015 1500 1509
6. N.J. Stone, J.G. Robinson, A.H. Lichtenstein, C.N. Bairey Merz, C.B. Blum, R.H. Eckel, and et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation. 129 25 Suppl 2 2014 S1 S45